New pharmacological options in the treatment of Alzheimer's disease

被引：2
|
作者：
Kleinova, L. [1 ,2 ]
Cerman, J. [2 ]
Hlavka, J. [3 ]
Hort, J. [2 ]
机构：
[1] 1 LF UK, Vseobecne Lekarstvi, Prague, Czech Republic
[2] Neurol Klin 2 LF UK, Kognitivni Ctr, V Uvalu 84, Prague 15006, Czech Republic
[3] Univ Southern Calif, Schaeffer Ctr Hlth Policy & Econ, Los Angeles, CA USA
来源：
CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE | 2022年 / 85卷 / 06期
关键词：
Alzheimer?s disease; phase three testing  of new drugs; β -amyloid; tau protein; neuroinflammatory theory; ric symptoms; neuroprotection; BETA; TRAMIPROSATE; INHIBITION; GUANFACINE; DEMENTIA; TRIAL;
D O I：
10.48095/cccsnn2022462
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
A new era of innovative treatment options for Alzheimer's disease is emerging. New goals of treatment are being developed with various monoclonal antibodies targeting potentially pathological molecules involved in the pathogenesis of Alzheimer's disease. The aim of this review is to acquaint the reader with new potential drugs, while most of those mentioned in this review are in the third phase of clinical trials.
引用
收藏
页码：462 / 469
页数：8
相关论文
共 50 条
  • [21] Current and future options in the treatment of Alzheimer's disease
    Fillit, HM
    FORMULARY, 2003, 38 : 8 - 10
  • [22] An update on drug treatment options of Alzheimer's disease
    Allgaier, Michael
    Allgaier, Clemens
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2014, 19 : 1344 - 1354
  • [23] PHARMACOLOGICAL ASPECTS OF GALANTAMINE FOR THE TREATMENT OF ALZHEIMER'S DISEASE
    Kim, Jae Kwang
    Park, Sang Un
    EXCLI JOURNAL, 2017, 16 : 35 - 39
  • [24] Current approaches to the pharmacological treatment of Alzheimer's disease
    Tan, Edwin C. K.
    Hilmer, Sarah N.
    Garcia-Ptacek, Sara
    Bell, J. Simon
    AUSTRALIAN JOURNAL OF GENERAL PRACTICE, 2018, 47 (09) : 586 - 592
  • [25] Pharmacological treatment in behavioral disturbances in Alzheimer's disease
    Suarez Gomez, M.
    Farinha, S.
    Barbosa, P.
    Isaac, J.
    Moura, P.
    Matos-Pires, A.
    Colaco, P.
    Caeiro, L.
    EUROPEAN PSYCHIATRY, 2019, 56 : S177 - S177
  • [26] Molecular rationale for the pharmacological treatment of Alzheimer's disease
    Zimmermann, M
    Gardoni, F
    Di Luca, M
    DRUGS & AGING, 2005, 22 : 27 - 37
  • [27] Pharmacological treatment of cognitive disorders in Alzheimer's disease
    Senin, U
    Cherubini, A
    Palumbo, B
    Mecocci, P
    FUNCTIONAL NEUROLOGY, 1997, 12 (3-4) : 211 - 212
  • [28] Pharmacological Chaperone Use for Treatment of Alzheimer's Disease
    Romero, L.
    Ergel, B.
    Petsko, G.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2016, 64 : S262 - S262
  • [29] Pharmacological treatment of cognitive deficits in Alzheimer's disease
    Brodaty, H
    Ames, D
    Boundy, KL
    Hecker, J
    Snowdon, J
    Storey, E
    Yates, MW
    MEDICAL JOURNAL OF AUSTRALIA, 2001, 175 (06) : 324 - 329
  • [30] THE PHARMACOLOGICAL RATIONALE FOR COMBINATION TREATMENT IN ALZHEIMER'S DISEASE
    Francis, P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2011, 18 : 658 - 658
12345